Wuhan YZY Biopharma Co., Ltd. (YZYBIO, 02496) published its third Environmental, Social and Governance (ESG) report, covering the calendar year 2025 and prepared under the Hong Kong Stock Exchange Appendix C2 ESG Reporting Code.
Governance and strategy • The Board retained ultimate responsibility for ESG matters, reviewed targets and approved the 2025 report, while an EHS Committee oversaw execution and reported regularly. • Climate risk assessment identified two physical and two transition risks; mitigation actions include facility hardening, diversified sourcing and energy-efficiency upgrades.
R&D and innovation • Total R&D investment reached RMB 78.20 million, supporting four clinical-stage and two pre-clinical bispecific antibody pipelines. • The core assets—M701 (Phase III, malignant ascites) and Y101D (Phase Ib/II, pancreatic cancer)—advanced clinical programmes. • Intellectual-property portfolio expanded to 44 granted patents (27 China, 17 overseas), 37 applications under review and 30 registered trademarks.
Product quality and safety • A four-tier quality-management system aligned with GMP, GCP, GDP and GVP standards governs the full product life cycle. • Thirty-two third-party audits were conducted across two ongoing clinical trials with no severe findings; no product recalls or subject complaints were reported.
Supply-chain oversight • The company worked with 161 suppliers (49% in South China, 35% Central China). All suppliers completed environmental- and social-risk questionnaires; five underwent on-site audits. • A “Supplier Sunshine Cooperation Agreement” requires zero tolerance for bribery; no corruption cases occurred during the year.
Environmental performance and targets • Per-capita carbon emissions fell 9% year on year, advancing toward the 2026 target of a 5% cut from the 2022 base. • Total greenhouse-gas emissions were 481.88 tCO₂-e (Scope 1: 3.46 t; Scope 2: 455.42 t; Scope 3 business travel: 22.99 t). • Energy use totalled 114.31 tce; electricity consumption was 6.87 million kWh. • Water consumption amounted to 2,359 t with no reported shortages. • Hazardous waste generated 6.23 t; non-hazardous waste 7 t.
Social metrics • Headcount stood at 113 (58% female). Employee turnover rate was 18.58%. • All staff received training, totalling 2,775 participant-times and averaging 10.7 hours per employee. • No work-related fatalities or injuries were recorded; 100% of employees were covered by work-injury insurance and annual health checks.
Community and industry engagement • Interim Phase II data for M701 in malignant pleural effusion were presented at the 2025 ESMO Congress; results were also published in Experimental Hematology & Oncology. • Partnerships with academic institutions included hosting graduate students from the Wuhan Institute of Virology for industry exchanges.
Outlook The report confirms YZYBIO’s commitment to align operational growth with rigorous ESG standards, advance bispecific antibody research and progress toward defined 2026 environmental targets.